A potential new drug to prevent Alzheimer’s disease in people with the so-called Alzheimer’s gene has been discovered by a University of Arkansas for Medical Sciences (UAMS) research team led by Sue Griffin, Ph.D.
The Proton Center of Arkansas opened today at the University of Arkansas for Medical Sciences (UAMS), becoming the first proton therapy center in Arkansas and only the 43rd in the nation to provide the most advanced cancer radiation treatment in the world.
The Birrer Laboratory at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute helped discover a proteogenomic signature in ovarian cancer that may improve the way the disease is treated around the world. The discovery, which identifies a 64-protein-gene signature that can predict primary treatment resistance in patients with high grade ovarian cancer, was published Aug. 3 in the journal Cell.
The first Arkansan and only second person in the world has received an innovative prosthetic hand, developed by researchers at the Institute for Integrative and Innovative Research (I³R), that restores a meaningful sense of touch and grip force following surgery at the University of Arkansas for Medical Sciences (UAMS).
Researchers from the University of Arkansas for Medical Sciences (UAMS) evaluated the accuracy of various hearing screening tools in a rural school setting in a recent article published by Ear and Hearing, the official journal of the American Auditory Society.
The Children’s Tumor Foundation (CTF) and the University of Arkansas for Medical Sciences (UAMS) announced the opening of the first CTF-sponsored, fully multidisciplinary clinic dedicated to the care of adults with neurofibromatosis (NF) at the UAMS Winthrop P. Rockefeller Cancer Institute.
The Hearing Norton Sound study, which focused on school-based hearing screening programs in rural Alaska, showed that referring children to specialists via telemedicine provides significantly quicker access to follow-up care than referring them to primary care providers.
Results of a 12-month multicenter randomized clinical trial led by Erika Petersen, M.D., a professor of neurosurgery at the University of Arkansas for Medical Sciences (UAMS), were published online Nov. 29 in Diabetes Care, highlighting the benefits of a breakthrough treatment for patients with painful diabetic neuropathy (PDN).
The University of Arkansas for Medical Sciences (UAMS) has received $18.9 million from the National Institutes of Health (NIH) to support new research and interventions that will focus on reducing cancer and cardiovascular disease disparities among people who live in rural areas and African American populations across Arkansas.
A research team has identified a potential cause of long-lasting symptoms experienced by COVID-19 patients, often referred to as long-haulers. The findings were published in the journal, The Public Library of Science ONE (PLOS ONE).
Data experts with the University of Arkansas for Medical Sciences (UAMS) have uploaded clinical images of COVID-19 patients to a publically available national database that scientists can use in researching the disease and its impact in a global pandemic.
Early results from a University of Arkansas for Medical Sciences (UAMS)-led COVID-19 antibody study show that 3.5% of Arkansans have been infected with the novel coronavirus.
The University of Arkansas for Medical Sciences (UAMS) has developed and begun using high-accuracy antibody testing to determine the magnitude of COVID-19 infection in Arkansas and inform the decisions of policymakers.
The latest issue of PLOS Genetics includes two publications that challenge the basic assumptions behind 24 years of bone and metabolism research, and given the magnitude of the potential paradigm shift, the editors turned to Stavros C. Manolagas, M.D., Ph.D., of the University of Arkansas for Medical Sciences (UAMS) to provide expert commentary and context.
Researcher Robert Eoff, Ph.D., has received a $1.2 million grant from the National Science Foundation to continue his work at the University of Arkansas for Medical Sciences (UAMS) on DNA damage, cell replication and its implications for diseases like dementia, ALS and cancer.
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences (UAMS) has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes in the DNA sequence that effects the development and advancement of multiple myeloma, a cancer of plasma cells in the blood.
The University of Arkansas for Medical Sciences (UAMS) Translational Research Institute announced today it will receive five years of federal funding totaling $24.2 million to accelerate research that addresses Arkansas’ biggest health challenges. The Translational Research Institute helps researchers turn their ideas and findings into new medical treatments and other health interventions. Its focus is on rural Arkansas populations, where health and health care disparities persist. A major emphasis of the award is research partnerships with Arkansas communities to ensure that research supported by the institute aligns with the priorities and needs of Arkansans.
A University of Arkansas for Medical Sciences (UAMS) research team led by Vladimir Zharov, Ph.D., D.Sc., has demonstrated the ability to detect and kill circulating tumor cells (CTCs) in the blood using a noninvasive device called Cytophone that integrates a laser, ultrasound and phone technologies. This device is 1,000 times more sensitive than other methods at detecting of CTCs in the blood of patients with melanoma, a deadly form of skin cancer.
An international research collaboration that includes the University of Arkansas for Medical Sciences (UAMS) has discovered that aging in nematodes (worms) can be slowed and even reversed by a number of Food and Drug Administration (FDA)-approved drugs, findings that have the potential to extend human lifespan. The study findings are published in Scientific Reports.
Roger D. Pechous, Ph.D., studies the bacteria that caused the infamous black death of the Middle Ages, shedding light on something old to potentially protect against something new: bioterrorism.
If knowledge is power, then the five women who just completed UAMS’s first CenteringPregnancy program will be super moms.
Alventena Cobb of Conway is a professional musician. She’s played the violin for more than 30 years and has instructed many students.
Charlotte and Emelia Dubs are just starting to toddle around their world. The 1-year-old twin girls from Conway spend their days exploring, laughing, blowing kisses and keeping their parents, Kenzie Butcher-Dubs and Morgan Dubs, on their toes.
A recent study by University of Arkansas for Medical Sciences (UAMS) and Central Arkansas Veterans Healthcare System (CAVHS) researchers shows that a type of blood protein we are all born with protects against osteoporosis, illuminating the potential for a novel approach to treatment.
The University of Arkansas for Medical Sciences (UAMS) is attacking the nationwide opioid epidemic on multiple fronts that have produced new research and treatment options for patients and health care providers across Arkansas and beyond.
The first memory David Scott has following his traffic accident July 31, 2017, is a paramedic leaning over trying to help release him from underneath his 18-wheeler.
But the statewide tele-stroke network and quick-responding emergency medical professionals in Bald Knob and Searcy all saved him precious time in stroke treatment and ensured that the saved time meant a saved life.
Castleman disease, a rare disorder of the lymph nodes and related tissues, was identified and named more than a half-century ago but, until recently, no one had written a book exclusively about it. Frits van Rhee, M.D., Ph.D., professor of medicine and director of developmental and translational medicine at the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS), has changed that.
TIna Farber arrived in Arkansas with one thing on her mind — meeting her two new grandbabies. Her son’s third child had arrived in April, and her daughter was expecting her third about one month later.
The single biggest factor determining whether a patient is likely to use opioids long term may be the number of days’ supply initially prescribed, according to a study by UAMS researchers.
A team of University of Arkansas for Medical Sciences (UAMS) research scientists recently received a $422,610 grant from the National Science Foundation to study the mechanisms of control of emotional responses of men and women using functional magnetic resonance imaging (fMRI).
Two residents from the University of Arkansas for Medical Sciences (UAMS) have been selected for a prestigious fellowship in neuro-oncology administered jointly by the Johns Hopkins University School of Medicine and the National Institutes of Health Neuro-Oncology Branch.
A University of Arkansas for Medical Sciences (UAMS) research team led by Vladimir Zharov, Ph.D., D.Sc., has demonstrated the ability to kill single cancer cells using the world’s smallest laser.
Some people who use so-called synthetic marijuana, known by names such as K2 and Spice, may be unable to metabolize the drug, leading them to experience its most harmful effects, a UAMS researcher said today at a national scientific meeting in Chicago.
Steve Schexnayder, M.D., has been appointed to the International Liaison Committee on Resuscitation (ILCOR) Pediatric Task Force, which reviews the latest science to develop pediatric resuscitation guidelines used throughout the world.
In the first national study on the topic, a University of Arkansas for Medical Sciences (UAMS) researcher found evidence to suggest that fewer pregnant women with a mildly underactive thyroid should be treated than previously recommended.
The University of Arkansas for Medical Sciences (UAMS) is collaborating with Dana-Farber Cancer Institute and Celgene Corp. to compile the largest set of high-quality
A woman had a cold virus injected into her brain tumor in an effort to eradicate it, making her the first person in the United States to participate in a clinical trial using this method, which incorporates immunotherapy, and was performed by doctors at the University of Arkansas for Medical Sciences (UAMS).
Sue Griffin, Ph.D., an internationally known Alzheimer’s disease researcher at the University of Arkansas for Medical Sciences (UAMS), leads a team that has received a five-year, $10 million grant from the National Institutes of Health (NIH) to study the causes and possible treatments for Alzheimer’s disease.
Called Our Community, Our Health, the discussion will include a panel with UAMS experts in women’s heart health and an Arkansan with a family history of fatal heart disease. The event will begin with a reception at 4:30 p.m. followed by the town hall from 5-6 p.m. at the UAMS Donald W. Reynolds Institute on Aging, 629 Jack Stephens Drive, Room 1207. For those who prefer to view and participate online, login at http://bit.ly/1YbqKfM.
Family presence when a child is undergoing tracheal intubation in a pediatric intensive care unit (PICU) can safely be implemented as part of a family-centered care model, reported a research team led by a University of Arkansas for Medical Sciences (UAMS) professor in the March 7 issue of JAMA Pediatrics.
Researchers from the University of Arkansas for Medical Sciences (UAMS) and other institutions are reporting the discovery of the first broad spectrum drug that can potently kill senescent (or aging) cells in culture and effectively clear the cells in animals by specifically targeting a pathway that is critical for the survival of senescent cells.
The University of Arkansas for Medical Sciences (UAMS) has become home to The Cancer Imaging Archive of the National Cancer Institute (NCI) with the transfer to UAMS of more than 40 terabytes of data from the archive’s former home at Washington University in St. Louis.
New findings on juvenile myelomonocytic leukemia (JMML) by researchers at the University of Arkansas for Medical Sciences (UAMS) and collaborators at other institutions were published online Oct. 12 by the medical journal Nature Genetics.
Identifying a patient’s genetic mutation led University of Arkansas for Medical Sciences (UAMS) physician-researcher Ling Gao, M.D., Ph.D., to an existing drug that eliminated the patient’s stage IV Merkel-cell carcinoma. Gao’s findings, made in collaboration with two other UAMS researchers, were published today in The New England Journal of Medicine. Metastatic Merkel-cell carcinoma is often fatal and there is no effective treatment. Gao’s 86-year-old female patient was diagnosed in 2013 with stage IIIB Merkel-cell carcinoma of the right temple. She had surgery and received radiation therapy in May 2013 and additional surgery in July 2014. In November 2014, doctors confirmed that the cancer had metastasized.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., was awarded a $1.7 million grant by the National Cancer Institute for clinical testing of a new technology called Theranostics, which is an integration of early diagnosis and treatment of melanoma.
The University of Arkansas for Medical Sciences (UAMS) Medical Center recently became the only Arkansas hospital to earn the 2015 Most Wired Award from the American Hospital Association Health Forum and the College of Healthcare Information Management Executives (CHIME).
The therapies are designed to reduce or prevent the euphoric rush that drug users crave by keeping methamphetamine in the bloodstream and out of the brain, where the drug exerts its most powerful effects.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., recently was awarded a $1.5 million R01 grant by the National Institutes of Health to investigate his diagnostic concept — “In vivo reading written in blood” — with new stimuli-responsive nanoparticles circulating in blood.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., recently was awarded a $1.5 million R01 grant by the National Institutes of Health to investigate his diagnostic concept — “In vivo reading written in blood” — with new stimuli-responsive nanoparticles circulating in blood.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right